<?xml version="1.0" encoding="UTF-8"?>
<p id="Par92">Psoriasis is a chronic autoimmune inflammatory disorder that causes skin cell overproduction and is characterized by raised, inflamed, red lesions and plaques that are accompanied by physical pain and itching. Guselkumab (Tremfya) is a fully human antibody developed by Janssen that neutralizes anti-IL-23. The HuCAL antibody library was used to generate guselkumab under a license from MorphoSys [
 <xref ref-type="bibr" rid="CR152">152</xref>, 
 <xref ref-type="bibr" rid="CR153">153</xref>]. In 2017, guselkumab was granted marketing approval by the US FDA for the treatment of plaque psoriasis [
 <xref ref-type="bibr" rid="CR154">154</xref>].
</p>
